Drugs / Proflavine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT02420665 | Sep 2015 → May 2021 | cervical cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01384864 | Aug 2011 → Dec 2015 | Barrett esophagus, intraepithelial neoplasia | Anandasabapathy, Sharmila, M.D. | Completed | No outcome recorded |
| Phase 0 | NCT01384708 | Aug 2010 → Oct 2013 | squamous cell carcinoma | Anandasabapathy, Sharmila, M.D. | Completed | No outcome recorded |
| Phase 0 | NCT01384695 | Jun 2009 → Feb 2014 | Barrett esophagus, gastroesophageal reflux disease | Anandasabapathy, Sharmila, M.D. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT02207959 | Jan → Jun 2015 | gastric cancer | Susana Gonzalez | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02029937 | Jan 2014 → Dec 2021 | squamous cell neoplasm | Anandasabapathy, Sharmila, M.D. | Unknown | Met primary |
| Phase 2 | NCT02018367 | Sep 2012 → Dec 2021 | Barrett esophagus | Anandasabapathy, Sharmila, M.D. | Unknown | No outcome recorded |
| Phase 2 | NCT02095847 | ? → Mar 2015 | uterine cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02206048 | Oct 2015 → Apr 2021 | cervical carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT02714439 Background | Oct 2016 → Feb 2024 | cervical cancer | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 0 | NCT01384240 Background | Apr 2010 → Jul 2013 | colon dysplasia, polyp of colon | Anandasabapathy, Sharmila, M.D. | Terminated | No outcome recorded |
| — | NCT05554133 Background | Jun 2023 → Mar 2027 expected | mouth disorder | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT01269190 Background | Dec 2010 → Dec 2028 expected | oral cavity neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proflavine | “Proflavine” NCT01384240 ↗ |
| Known as | proflavine hemisulfate | “A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to...” NCT05554133 ↗1“Drug: Proflavine Hemisulfate” NCT01384240 ↗ |
| Modality | Diagnostic / imaging agent | “confocal imaging using contrast agent proflavine” NCT01384695 ↗ |
| Route | Topical | “5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.” NCT02018367 ↗ |